LLY - Eli Lilly and Company Stock Analysis & Valuation

Eli Lilly and Company (LLY) trades at $1417.54 with an EquitAI Valuation DNA score of 5/10 and Quality score of 10/10. The company's trailing P/E ratio is 45.9x. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Wall Street analysts have a consensus 12-month price target of $1433.7 for Eli Lilly and Company (LLY), representing an implied 1.1% upside from its current trading level of $1417.54 with an average rating of Buy based on 20 analyst ratings. Individual analyst price targets range from a low of $940.0 to a high of $1650.0, with a median forecast of $1435.0. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Eli Lilly and Company has an indicated annual dividend yield of 0.59%. Dividend stability is factored into its Income DNA pillar alongside free cash flow coverage.

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.